- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Okyo Pharma chairman increases stake with new share acquisition | 1 | Investing.com | ||
| Fr | Okyo Pharma: Chairman stockt Beteiligung nach Kursrückgang auf | 2 | Investing.com Deutsch | ||
| Fr | OKYO Pharma Announces Chairman and Founder Acquires Shares | 243 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 21, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 18.11. | OKYO Pharma to Present at OIS XV in San Diego | 157 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 18, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 18.11. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 29.10. | OKYO Pharma to Present at BIO-Europe 2025 in Vienna | 257 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 29, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 29.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.10. | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 16.10. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 224 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 16.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 206 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 350 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 653,80 | +0,12 % | IDEXX Laboratories Vs ResMed: Which Stock Could Rally? | ||
| BIOXCEL THERAPEUTICS | 1,664 | -1,42 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,052 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,572 | +0,28 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,108 | +16,84 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| CELLAVISION | 14,900 | +4,34 % | CellaVision: Softer Quarter with Mixed Regional Performance | Organic sales growth:Q3, 2025: 2.6% (9.4)EBITDA margin:Q3, 2025: 28% (27)July 1st - September 30th, 2025Net sales decreased by -1.7% (6.4) to SEK 176 m (179).Sales increased organically by 2.6% (9.4)... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,460 | +0,90 % | Precision BioSciences launches $75M stock and warrant offering | ||
| ZYMEWORKS | 21,600 | -0,92 % | Zymeworks Inc.: Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer | VANCOUVER, British Columbia, Nov. 18, 2025(Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics... ► Artikel lesen | |
| VTV THERAPEUTICS | 26,800 | +1,52 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 16,850 | +1,51 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,370 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Inc. Sends Letter to Stockholders | Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote "FOR" BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025... ► Artikel lesen | |
| NUVATION BIO | 7,475 | +0,47 % | Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage | ||
| MIRA PHARMACEUTICALS | 1,190 | +4,39 % | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,400 | +2,19 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE... ► Artikel lesen | |
| ONCONETIX | 2,160 | 0,00 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,33 % bei einem Aktienkurs von 1,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.